Table 1.
Baseline demographics of participants.
| Control Group (n = 22) |
SRT Group (n = 22) |
p-Value | |
|---|---|---|---|
| Age (years) | 47.1 ± 9.1 | 43.6 ± 7.7 | 0.181 |
| Sex, male/female (n) | 19/3 | 17/5 | 0.696 |
| Laterality, OD/OS (n) | 14/8 | 13/9 | 1.000 |
| Type of leakages by FFA (n, focal: diffuse) | 8:14 | 6:16 | 1.000 |
| FAF pattern at SRD (n, hyper-/hypo-autofluorescent) | 13/9 | 14/8 | 0.757 |
| Duration of symptom (months) | 12.9 ± 8.1 | 13.7 ± 12.7 | 0.822 |
| Prior intravitreal anti-VEGF injection, n (%) | 10 (45.5%) | 9 (40.9%) | 1.000 |
| BCVA (LogMAR) | 0.20 ± 0.14 | 0.25 ± 0.22 | 0.428 |
| Central macular thickness (μm) | 316.1 ± 94.0 | 335.0 ± 110.5 | 0.545 |
| Subretinal fluid height (μm) | 186.5 ± 84.1 | 173.4 ± 88.6 | 0.617 |
| Central choroidal thickness (μm) | 369.8 ± 76.2 | 351.4 ± 63.0 | 0.566 |
| Mean retinal sensitivity (dB) | 19.3 ± 3.8 | 19.5 ± 3.7 | 0.904 |
VEGF, Vascular endothelial growth factor; BCVA, best-corrected visual acuity; FFA, fundus fluorescein angiography; FAF, fundus autofluorescence; SRD, serous retinal detachment.